About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
MARIO
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
October 2023
SCY-247, A SECOND-GENERATION IV/ORAL TRITERPENOID ANTIFUNGAL:
IN VITRO
ACTIVITY AGAINST A BROADSPECTRUM OF FUNGAL PATHOGENS, AND DOSE-DEPENDENT TISSUE DISTRIBUTION
IN VIVO
TIMM, October 2023
April 2023
Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open Label Studies: Difficult to Treat Invasive Fungal Infections (FURI) and Infections with
Candida auris
(CARES)
ECCMID, April 2023
April 2023
FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Treated with Oral Ibrexafungerp
ECCMID, April 2023
April 2023
A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step Down Therapy following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall Therapy
ECCMID, April 2023
October 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)
IDWeek
September 2022
Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
ISHAM
September 2022
Outcomes of Oral Ibrexafungerp in Refractory Patients with Candida from an Interim Analysis of a Phase 3 Open-Label Study (FURI)
MSGERC
September 2022
Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study
MSGERC
September 2022
CANDLE: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Once Monthly Oral Ibrexafungerp for Prevention of Recurrent Vulvovaginal Candidiasis (VVC)
NPWH
September 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)
ISHAM
< Prev
Next >
Please ensure Javascript is enabled for purposes of
website accessibility